Expert pearls in posterior capsule opacification after cataract surgery

Posterior capsule opacification (PCO) remains one of the most common longer-term complications after cataract surgery and can have a meaningful impact on visual quality, patient satisfaction and postoperative outcomes. Although neodymium-doped yttrium aluminum garnet (Nd) laser capsulotomy is a well-established treatment, careful patient selection, timing, laser technique and postoperative management remain important to minimize complications and optimize results.

Dr Joobin Khadamy (Capio Globen Eye Clinic, Stockholm) shares his practical considerations involved in managing PCO after cataract surgery. In this Q&A, Dr Khadamy discusses when to consider Nd:YAG capsulotomy, situations in which treatment should be delayed, technical pearls for capsulotomy, higher-risk patient groups and strategies to reduce the risk or severity of PCO at the time of cataract surgery.

Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.

Register Register

When is the right time to consider Nd:YAG capsulotomy, and are there situations where you would delay treatment?

I do not think there is a single “correct” time, but after uncomplicated cataract surgery I usually prefer to wait around 3 months before considering Nd:YAG capsulotomy. Occasionally, I will intervene earlier in patients with dense fibrotic PCO, significant capsular contraction or visually disabling PCO after refractive cataract surgery.

Equally important is recognizing when not to perform Nd:YAG capsulotomy. If there is active inflammation, recent cystoid macular edema (CME), unstable retinal disease or a recent symptomatic posterior vitreous detachment, I would usually postpone treatment.

One of my own rules is to avoid Nd:YAG capsulotomy whenever I think there is a realistic chance that the patient may need intraocular lens (IOL) rotation or IOL exchange in the future. Preserving an intact posterior capsule makes any secondary IOL surgery considerably easier and safer.

A rare but important situation is persistent low-grade inflammation associated with a capsular plaque. In these patients, chronic Cutibacterium acnes endophthalmitis should always be considered before opening the capsule.

What factors influence your Nd technique, including capsulotomy size, location and energy settings?

My goal is simple: use the lowest effective energy while creating an opening that completely solves the patient’s visual problem. I usually create an opening slightly larger than the photopic pupil, although I tend to make it more generous in patients with premium IOLs. If there is zonular weakness or concern about IOL stability, I may be more conservative.

The capsule itself often dictates the technique. Dense fibrotic membranes frequently require much more energy than textbooks suggest. In these situations, multiple cavitation bubbles can temporarily obscure the view, making it harder to focus accurately and increasing the risk of IOL pitting. Extensive laser treatment can also lead to more postoperative inflammation and intraocular pressure (IOP) elevation.

One practical pearl that is not discussed very often is making sure that partially detached capsular or vitreous strands are completely released. If they remain attached to the edge of the capsulotomy, they can continue to move across the visual axis and become a persistent source of postoperative floaters.

If I find myself repeatedly increasing the laser energy without making real progress, I stop and rethink the strategy. Sometimes, a controlled surgical membranectomy is simply the better option.

Which patients require extra caution before or after Nd:YAG capsulotomy?

I pay particular attention to patients with glaucoma or ocular hypertension because of the risk of postoperative pressure spikes. I am also more cautious in younger patients with high myopia before they have developed a complete posterior vitreous detachment, as vitreoretinal traction may be greater.

Patients with vitreomacular traction, epiretinal membrane, previous CME, retinal tears, retinal detachment or active neovascular age-related macular degeneration also deserve a more individualized assessment before treatment.

Retinal detachment and CME are recognized complications of Nd:YAG capsulotomy, but I think the current evidence is reassuring. The absolute risk appears to be relatively low, particularly with modern cataract surgery, and the patient’s underlying ocular risk factors are probably more important than the laser procedure itself.

What practical steps can cataract surgeons take at the time of surgery to reduce the risk or severity of PCO?

To me, the principle is straightforward: residual lens epithelial cells need both viable cells and space to migrate. If you eliminate one, or ideally both, you dramatically reduce the chance of clinically significant PCO.

Meticulous cortical clean-up is therefore fundamental. I also try to remove residual lens epithelial cells whenever this can be done safely, completely remove the ophthalmic viscosurgical device (OVD) and achieve a well-centered capsulorhexis with full 360-degree optic overlap.

Perhaps the most important design feature of a modern IOL is a continuous 360-degree sharp posterior square edge with appropriate posterior optic angulation. This creates a mechanical barrier that minimizes the potential space between the optic and the posterior capsule, limiting lens epithelial cell migration.

In my own practice, I also find that vigorous irrigation with a standard balanced salt solution (BSS) cannula to release residual cortical material and cortical plaques can be very helpful. In selected cases, primary posterior capsulotomy or peeling posterior capsular plaques may be appropriate. Anterior capsule polishing probably reduces capsular fibrosis and phimosis, although its role in preventing true PCO remains less certain.

What postoperative medications do you prescribe after Nd:YAG capsulotomy, and in which patients?

I do not use exactly the same regimen for every patient.

For straightforward, low-energy capsulotomies, many patients need little or no postoperative anti-inflammatory treatment. However, if I have used high laser energy or treated dense fibrotic PCO, or if the patient has uveitis or a history of CME, I usually prescribe a short course of topical corticosteroids.

I reserve topical nonsteroidal anti-inflammatory drugs mainly for patients at higher risk of postoperative CME, such as those with diabetes, previous CME, epiretinal membrane, vitreomacular traction or uveitis.

Similarly, I individualize prophylaxis against pressure spikes. Patients with glaucoma, ocular hypertension, advanced optic nerve damage or extensive laser treatment often receive prophylactic IOP-lowering medication, together with early postoperative pressure monitoring.

Overall, I think postoperative treatment should be tailored to the patient and the procedure rather than prescribed routinely.

What are the most common mistakes made before or during Nd:YAG capsulotomy, and how can they be avoided?

A key mistake is assuming that every patient with reduced vision and some degree of capsular wrinkling or opacification after cataract surgery has clinically significant posterior capsule opacification (PCO). Careful slit-lamp examination, including assessment of the red reflex and retroillumination, is essential to confirm that the posterior capsule is truly responsible for the patient’s symptoms. Laser treatment should only be performed after this has been confirmed.

One of the most common masqueraders is intraocular lens (IOL) opacification. In selected cases, I find anterior segment optical coherence tomography surprisingly useful. It allows precise localization of the opacity, helps distinguish true PCO from IOL opacification, and can also support the diagnosis of late capsular bag distension syndrome, or liquefied after-cataract, which can closely mimic routine PCO.

Another common pitfall is performing Nd:YAG capsulotomy capsulotomy too early in patients who may later require IOL rotation or exchange. Once the posterior capsule has been opened, these procedures become significantly more challenging and carry increased risk.

From a technical standpoint, it is important to ensure that the laser is focused just posterior to the capsule before each shot. Failure to achieve the correct posterior focus offset is a common cause of unnecessary IOL pitting.

When performing the capsulotomy, the goal should be to create an opening large enough to restore visual quality while avoiding making it unnecessarily larger than the optic. An excessively large capsulotomy may increase the risk of vitreous prolapse into the anterior chamber and IOL instability.

Surgeons may also continue increasing laser energy when they should instead reconsider the treatment strategy. Dense fibrotic membranes are not always ideal for laser treatment and may sometimes be better managed surgically.

Finally, it is important to ensure that any partially detached capsular or vitreous strands are completely released. Residual strands attached to the capsulotomy edge can remain mobile and are often identified by asking the patient to look in different directions during the procedure.